Target intelligence / Profile preview

Exostosin glycosyltransferase 1 (EXT1)

Target
EXT1
Molecular classification
Enzyme, Glycosyltransferase, Heparan sulfate co-polymerase subunit
01

Overview

Exostosin glycosyltransferase 1 (EXT1) is a membrane-bound enzyme localized to the Golgi apparatus, responsible for catalyzing the polymerization of heparan sulfate chains by alternately adding N-acetylglucosamine and glucuronic acid units to growing proteoglycans. EXT1 usually functions as a heterodimeric complex with EXT2, forming an obligate assembly essential for normal heparan sulfate biosynthesis. EXT1 is regarded as a putative tumor suppressor, and mutations in its gene cause hereditary multiple exostoses, a disorder marked by benign bone tumors (osteochondromas), as well as other skeletal malformations in syndromes such as Trichorhinophalangeal syndrome type II. EXT1 is bi-functional, containing both GlcA-transferase and GlcNAc-transferase domains, but its GlcA-transferase activity is indispensable for the formation of heparan sulfate chains, and most disease-causing mutations cluster in its catalytic domain. The enzyme participates in key developmental and cellular processes, including regulation of cell signaling, angiogenesis, and blood coagulation.

Other names
Exostosin-1ttvExostosin glycosyltransferase 1Heparan sulfate co-polymerase subunit EXT1Multiple exostoses protein 1N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferaseGlucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferaseEXTLGCRLGSTRPS2TTVexostoses (multiple) 1Langer-Giedion syndrome chromosome region protein
02

Biological functions

Heparan sulfate biosynthesis (chain polymerization/elongation)Regulation of blood clottingAngiogenesis (formation of blood vessels)Cell signaling via proteoglycansTumor suppressionModification of newly produced enzymes and proteins in Golgi apparatus
03

Disease associations

Hereditary multiple osteochondromas (multiple exostoses)Tricho-rhino-phalangeal syndrome type IICancer/metastasis (through heparan sulfate modification)Bone and joint malformations
04

Safety considerations

Loss-of-function mutations lead to abnormal bone growth and skeletal deformitiesTumorigenesis risks (benign bone tumors)
05

Biomarkers

Genetic mutations in EXT1 (for diagnosis of hereditary multiple osteochondromas and Trichorhinophalangeal syndrome II)Loss-of-function mutations detectable via genetic testing

Beyond the preview

Go deeper on Exostosin glycosyltransferase 1 (EXT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exostosin glycosyltransferase 1 (EXT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call